Skip to main content
Premium Trial:

Request an Annual Quote

ICx Wins Mass Spec Contract for South Korea

NEW YORK (GenomeWeb News) – ICx Technologies has been awarded a multi-year contract worth up to $40 million to work with partners to develop a biological and chemical mass spectrometer for use by the South Korean military.

ICx said that its ICx Analytical Instruments business it will work jointly with ICx BioDefense to deliver a system capable of detecting both chemical and biological warfare agents that will be used in South Korean military reconnaissance vehicles.

The system will be based on the Griffin 450 mass spectrometry platform, said Dennis Barket, president of ICx Analytical Instruments, in a statement.

ICx will partner on the project with Hankuk Communication Company, located in Seoul, through Annapolis, Md.-based Tradeways, Barket said.

"Terrorism and asymmetric warfare are global problems, and we are pleased that the quality of our sensors and solutions are being recognized on an international level," ICx Technologies CEO Hans Kobler said.

ICx Technologies specializes in integrating and developing advanced sensor technologies for homeland security, force protection and commercial applications.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.